OrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co., Ltd. for the Treatment of Type 2 Diabetes – BioSpace
Skip to main content Published: Nov 02, 2022 — Company announces positive Phase 1 clinical data of TLC-3595 to be presented at The Liver Meeting® 2022 —PALO ALTO, Calif.–(BUSINESS WIRE)–…